Moreover, by inhibiting CD47, the HDAC6/let-7i-5p/TSP1 axis decreased the neoplastic and antiphagocytic characteristics of HCC cells, presenting a prospective therapeutic target for HCC therapy [163]. Here, HDAC6 is linked to hepatocellular carcinoma.